The management of AKI hinges on identifying the underlying cause and treating it. The main objectives of initial management are to prevent cardiovascular collapse and death and to call for specialist advice from a
nephrologist. In addition to treatment of the underlying disorder, management of AKI routinely includes the avoidance of substances that are toxic to the kidneys, called
nephrotoxins. These include
NSAIDs such as
ibuprofen or
naproxen,
iodinated contrasts such as those used for
CT scans, many
antibiotics such as
gentamicin, and a range of other substances.
Intrinsic The myriad causes of intrinsic AKI require specific therapies. For example, intrinsic AKI due to vasculitis or glomerulonephritis may respond to
steroid medication,
cyclophosphamide, and (in some cases)
plasma exchange. Toxin-induced prerenal AKI often responds to discontinuation of the offending agent, such as ACE inhibitors, ARB antagonists,
aminoglycosides,
penicillins, NSAIDs, or
paracetamol. nor with any reduced mortality or length of
intensive care unit or hospital stay.
Postrenal If the cause is obstruction of the urinary tract, relief of the obstruction (with a
nephrostomy or
urinary catheter) may be necessary.
Renal replacement therapy Renal replacement therapy, such as with
hemodialysis, may be instituted in some cases of AKI. Renal replacement therapy can be applied intermittently (IRRT) and continuously (CRRT). Study results regarding differences in outcomes between IRRT and CRRT are inconsistent. A systematic review of the literature in 2008 demonstrated no difference in outcomes between the use of
intermittent hemodialysis and
continuous venovenous hemofiltration (CVVH) (a type of continuous hemodialysis). Among critically ill patients, intensive renal replacement therapy with CVVH does not appear to improve outcomes compared to less intensive intermittent hemodialysis. However, other clinical and health economic studies demonstrated that, initiation of CRRT is associated with a lower likelihood of chronic dialysis and was cost-effective compared with IRRT in patients with acute kidney injury.
Complications Metabolic acidosis,
hyperkalemia, and
pulmonary edema may require medical treatment with
sodium bicarbonate, antihyperkalemic measures, and diuretics. Lack of improvement with
fluid resuscitation, therapy-resistant hyperkalemia, metabolic acidosis, or fluid overload may necessitate
artificial support in the form of
dialysis or
hemofiltration. but the effect of a fluid load is highly variable. Striving toward a predefined urine output target to prevent AKI is futile.
Early recovery of AKI AKI recovery can be classified into three stages 1–3 based on the inverse of the AKI KDIGO serum
creatinine criteria. ==Prognosis==